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300mg is likely to be a cost-saving treatment option compared with sitagliptin 100 
mg when used in combination with other antihyperglycemic agents to treat T2DM.
PDB78
The cosT-effecTvenese of liragluTiDe vs exenaTiDe for The 
TreaTmenT of TyPe 2 DiaBeTes in The uniTeD sTaTes
Ning N., Hay J.W.
Schaeffer Center for Health Policy & Economic, Los Angeles, CA, USA
IntroductIon: The global clinical and economic burden of type 2 diabetes is 
substantial. New GLP-1 receptor agonists have shown a multifactorial clinical profile 
with the potential to address many of clinical needs. objectIves: The objective 
of this study is to evaluate the cost-effectiveness of once-daily liraglutide vs. once-
weekly exenatide in patients who had failed in metformin, sulfonylurea, or both 
treatments. Methods: A Markov model is made to predict life expectance and 
QALYs of liraglutide and exenatide. Baseline characteristics are consistent with 
DURATION-6 clinical trial. Simulations were run over 35 years (one year as a cycle) 
from a third-party payer perspective. Future costs and benefits are discounted at 
3%. 5 health states were included in the model: “No complications”, “Microvasular 
complications”, “Macrovasular complications”, “both complications” and “Death”. 
Data was extracted from previous studies, head-to-head clinical trial, U.S. con-
sumer Price Index, U.K. Perspective Diabetes Survey, Action in Diabetes and Vascular 
Disease trials, Action to Control Cardiovasular Risk in Diabetes trials and National 
Health Interview Survey data. The transition probabilities in the model vary by the 
age and gender of the patients to simulate the natural progression of type 2 diabe-
tes. results: Liraglutide is associated with improvement of 0.15 QALY. Even though 
it costs more than exenatide, it is still more cost-effective than exenatide. The incre-
mental cost-effectiveness ratios per QALY gained with liraglutide is $138,282 (2013 
US$), which is less than 3 times GDP per capita in 2013. Sensitivity analysis was 
done. Figures in the model were adjusted reasonably, and the results remain robust. 
In other word, liraglutide is more cost-effective than exenatide. conclusIons: 
Long-term projections indicated that liraglutide (injected daily) is more cost-effec-
tive than exenatide (applied weekly).
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conTrasTing cosT effecTiveness resulTs DeriveD from The ukPDs 68 
anD 82 risk equaTions in TyPe 2 DiaBeTes
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objectIves: The IMS CORE Diabetes Model (CDM) is a widely published and previ-
ously validated decision support tool. The model uses the UKPDS 68 risk equations 
(REs) to predict events and has been updated to include the UKPDS 82 REs. The 
objective of this study was to compare cost-effectiveness (CE) results obtained via 
the UKPDS 82 and 68 REs. Methods: Lifetime analyses were conducted using the 
CDM to evaluate the CE of metformin+ sulphonylurea (M+S) compared to metformin 
+ DPP-4 (M+D). Basal insulin rescue therapy (BI) was applied to both arms at HbA1c 
threshold levels of 7.5%. Efficacy data for dual therapy was sourced from a published 
mixed treatment comparison; HbA1c and BMI change of -0.8% and 0.199kg/m2 
(M+D);-0.79% and 0.707kg/m2 (M+S) and -0.82 and 0.545 kg/m2 (BI), respectively, 
were applied. Hypoglycemia rates were estimated based on odds ratios from the 
same systematic review. Results were obtained using for the UKPDS 82 and UKPDS 
68 REs. US 2012 costs were used and discounting was applied at 3.5%. results: 
Quality adjusted life expectancy was 8.157 and 8.038 in patients treated with M+D 
and M+S using UKPDS 68 REs and 7.851 and 7.733 using UKPDS 82 REs. Total direct 
costs were estimated at $77,656 and $66,276 respectively for patients treated with 
M+D and M+S using UKPDS 68 REs and $59,130 and $47,664 respectively using 
UKPDS 82 REs. Incremental differences between REs were less pronounced; incre-
mental costs per quality adjusted life year (QALY) gained were $96,088 and $97,545 
using UKPDS 68 compared to UKPDS 82 REs. conclusIons: The UKPDS risk equa-
tions are widely used in type 2 diabetes cost-effectiveness models. While the new 
equations predict appreciable differences in absolute costs and quality adjusted 
life expectancy the incremental differences were marginal. Consequently health 
economic evaluations using the new UKPDS82 equations appear unlikely to result 
in significantly different results compared with the UKPDS68 REs.
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illusTraTing The relaTionshiP BeTween The numBer of 
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esTimaTes of qualiTy of life imProvemenT in healTh economic 
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objectIves: Independent studies have demonstrated that the health utility gain 
associated with the per-event avoidance of non-severe hypoglycaemia episodes 
(NSHE) varies according the baseline rate. Despite this many health technology 
assessments persist in using a mean per-event health disutility. The objective of this 
study was to quantify the bias introduced into an economic evaluation when using 
an average (static) disutility compared to a baseline event rate adjusted (diminish-
ing) disutility. Methods: We compared the one year disutility of daytime NSHE 
for an increasing annual event rate of 1, 5, 10 and 20 events per year. Disutility was 
assessed using a published non-linear approach assuming diminishing marginal 
disutility (D1) and compared to a static approach (S1) assuming a constant utility 
decline of 0.0052 per NSHE. Incremental utility was assessed assuming a compara-
tor intervention associated with (A) 1 NSHE less per year and (B) a 50% reduction in 
NSHE rate. results: The disutilities associated with NSHE event rates of 1, 5, 10 and 
20 events per year were 0.014, 0.024, 0.031 and 0.039 respectively using the marginal 
disutility assumption (D1) and 0.005, 0.026, 0.052 and 0.104 respectively using the 
static approach (S1). Utility gain for 1 NSHE avoided per year was 0.014, 0.002, 0.001 
and 0.001 (D1) and 0.005, 0.005, 0.005 and 0.005 (S1), respectively. Assuming a 50% 
reduction in the rate of NSHE was associated with utility gains of 0.007, 0.005, 0.006 
objectIves: We conducted a cost-effectiveness analysis of two dipeptidyl-pepti-
dase inhibitors, saxagliptin and linagliptin, used in combination with metformin 
for the treatment of Type II diabetes. Methods: A decision tree model was devel-
oped using cost and effectiveness data for saxagliptin + metformin and linagliptin 
+ metformin using published literature. Costs were evaluated using third party 
payer’s perspective and included costs of drugs, physician visits, lab tests, hospital 
costs, and costs associated with adverse events. All costs were adjusted to 2013 
dollars using consumer price index and were calculated for a period of one year. A 
comprehensive literature review of Pubmed, Cochrane library and Google Scholar 
was conducted to obtain data for clinical efficacy and costs. Clinical efficacy values 
were obtained from randomized clinical trials. The primary efficacy measure was 
the proportion of participants achieving HbA1c levels < 7.0%. Base case analysis 
was analyzed as incremental cost per effective treatment. One way sensitivity 
analysis was performed by varying costs by 10% associated with drug treatment 
to evaluate the robustness of the model. results: In the base-case analysis, saxa-
gliptin was found to have better clinical outcomes and lower costs than linagliptin 
as a combination therapy with metformin with an incremental cost effectiveness 
ratio of 30.51. Considering only direct costs for the treatment, expected cost per 
effective treatment for a year was found to be $179.25 for saxagliptin while that 
for linagliptin was $298.99. Sensitivity analysis also indicated saxagliptin to be the 
dominant treatment option. conclusIons: Saxagliptin in our study was found 
to be favored over linagliptin in combination with metformin for the treatment 
of Type II Diabetes. These results may help decision makers develop appropriate 
treatment options. Type II diabetes being a lifestyle disorder, further research 
by inclusion of indirect costs associated with the treatment options may help 
strengthening the results.
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objectIves: Current treatment options for managing type 2 diabetes (T2D) have 
significant and varied effects upon patient weight and the incidence of hypogly-
caemia. In the short term, and from the patient’s perspective, the absolute clinical 
effects of therapies are usually observed in the year succeeding therapy initiation. 
Consequently there has been a growing interest among payers and providers to 
understand the influence of weight and hypoglycaemia on the cost-effectiveness 
of T2D treatments. Methods: With this in mind we developed an economic model 
that quantified the quality of life and cost consequences associated with different 
oral treatment strategies over a 1-year time horizon, focusing on the effect of weight 
change and incidence of hypoglycaemia. We illustrate these issues in patients add-
ing dapagliflozin (DAPA) or DPP-4 inhibitors (DPP-4i) to metformin mono-therapy 
(MET). Data describing costs, utilities and absenteeism were sourced from the pub-
lished literature. The model adopts a US societal perspective by including direct 
and indirect costs and benefits and US specific data where possible. results: The 
mean (95% CI) quality adjusted life year (QALY) difference in the DAPA vs. DPP-4i 
comparison (0.02: 0.75 vs. 0.73) was driven by the weight advantage of DAPA with 
no appreciable difference in expected costs ($34: $8,426 vs. $8,392): DAPA was cost-
effective with a cost per-QALY gained estimate of $2,090. conclusIons: In the 
context of this evaluation the driver of economic value over the 1-year period fol-
lowing therapy initiation was weight reduction mediated through quality of life 
gains; whilst a lower incidence of hypoglycaemia was associated with cost offsets in 
medical expenditure and quality of life gains, there was no appreciable difference in 
rates of hypoglycaemia, and hence hypoglycaemia did not drive cost-effectiveness, 
between the two groups.
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shorT-Term economic anD clinical ouTcomes of canagliflozin 
comPareD To siTagliPTin in The managemenT of TyPe 2 DiaBeTes 
melliTus (T2Dm)
Lopez J.M1, Martin S.1, Ektare V.2, Patel D.3, Rupnow M.F.1, Botteman M.F.2
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3Pharmerit North America LLC, Bethesda, MD, USA
objectIves: Short-term cost per outcome analyses focusing on efficient attain-
ment of desired health care outcomes, including quality measures can be useful 
decision-making tools for managed-care payers. Therefore, a simple cost-efficiency 
model was developed to compare the short-term (i.e., 1-year) clinical and economic 
outcomes of treating hyperglycemia with canagliflozin versus sitagliptin in people 
with T2DM. Methods: Data on clinical efficacy and key adverse events (AEs) were 
obtained from a pooled analysis of 2 comparative trials of canagliflozin 300 mg/
day versus sitagliptin100 mg/day. Wholesale drug acquisition costs were used. The 
total and diabetes-related cost savings associated with achieving (vs. not achieving) 
A1C< 7% was specified as $3,055/year and $1,651/year, respectively, based on previ-
ously reported claims database analysis. Savings of $288/year associated with 1% 
decrease in weight, sourced from the literature was applied. AE-related costs (i.e., 
$105-$154/genital mycotic infections and $532/hypoglycemia requiring third-party 
assistance) were derived from treatment algorithms, literature, and reimburse-
ment rates. Total costs, average and incremental costs/key outcomes were calcu-
lated. results: In the simplest analysis evaluating drug cost/outcome only, where 
annual drug-related costs were similar (canagliflozin 300 mg $3,660 vs sitagliptin 
$3,594), the average cost/patient achieving A1C< 7% were lower for canagliflozin 300 
mg compared to sitagliptin ($7,162 vs $8,398/patient per year, respectively). Likewise, 
the average cost per 1% reduction in A1C were lower for canagliflozin 300 mg versus 
sitagliptin ($3,893 vs $5,364). In a comprehensive analysis including medical, drug, 
and adverse event costs, canagliflozin 300 mg dominates sitagliptin in incremental 
cost efficiency in A1C goals. Canagliflozin 300 mg resulted in net savings of $639 per 
patient / year compared to sitagliptin. conclusIons: Based on inputs and assump-
tions used in this model, this 52-week economic analysis suggests that canagliflozin 
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a guideline-recommended intervention. Approximately 73% of interventions exam-
ined in diabetes CUAs were found to be either cost-saving or below $50,000 per QALY. 
Logistic regression analysis showed that higher-quality CUAs or CUAs conducted 
from the US perspective were more likely to report favorable ratios. Ratios for sur-
gical interventions and interventions recommended by diabetes guidelines were 
more favorable than other intervention types. Of 7,907 eligible patients in Humedica, 
6,500 could be shifted to cost-saving treatments, saving more than $11 million and 
gaining more than 1,800 QALYs. conclusIons: Our findings suggest that most 
diabetes interventions evaluated by CUAs are recommended by practice guidelines 
and may provide good value for money. Our results also indicate that patients and 
the health care system could benefit considerably from shifting to greater use of 
cost-saving interventions.
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weighT change anD healTh care resource use (hcru) in english 
PaTienTs wiTh TyPe 2 DiaBeTes melliTus (T2Dm) iniTiaTing a new 
anTiDiaBeTic Drug class
Rigney U.1, Blak B.T.1, Sternhufvud C.2, Ycas J.3, Racketa J.3, Hammar N.2
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objectIves: The contribution of weight change to the economic burden of T2DM 
is unclear. This study investigated associations between weight change and HCRU 
in patients with T2DM initiating new antidiabetic drug class. Methods: Patients 
with T2DM initiating new antidiabetic drug classes (first-line, switch or add-on) 
between 01/01/05-01/01/12 were identified in UK Clinical Practice Research Datalink 
primary care (PC) records linked with Hospital-Episode-Statistics. Baseline char-
acteristics were assessed before drug class initiation and weight change (index 
date) was observed 6 months after. HCRU was followed up to one year after index 
and included diabetes-related PC contacts and prescriptions, and all-cause hospi-
talisation days. Weight change was categorized as: < 3.0% change (weight-neutral), 
3.0%-5.4% gain (gain+), ≥ 5.5% gain (gain++), 3.0%-5.4% loss (loss+), ≥ 5.5% loss 
(loss++). Comparisons between weight groups were conducted using negative bino-
mial regression. results: Of 9031 patients with mean age 59.2 years and 57.4% 
men; 54.3% were weight-neutral, 12.0% gain+, 10.2% gain++, 12.8% loss+, 10.7% 
loss++. Mean baseline BMI ranged from 30.1 kg/m2 (gain++) to 33.8 kg/m2 (loss++). 
Follow-up crude mean PC contacts for all patients was 4.6 per person-year (PPY), 
mean prescriptions 15.3 PPY, mean hospitalisation days 1.5 PPY. For the weight-
neutral group, crude mean PC contacts, prescriptions and hospitalisation days were 
4.6, 14.9 and 1.2 PPY, respectively. In initial adjusted comparisons to weight-neutral 
patients, gain++ had more PC contacts, gain+ and gain++ had more prescriptions 
whereas loss+ patients had fewer. Gain+ and loss++ patients had more hospitali-
sation days than weight-neutral patients. conclusIons: T2DM patients gaining 
weight after initiating new antidiabetic treatment may have increased health care 
resource use compared to weight-neutral patients. Higher weight loss, possibly due 
to underlying health problems, may also be associated with increased resource use. 
Causal interpretations of these results require detailed information on social and 
medical factors driving resource use in diabetic patients that were unavailable.
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objectIves: This study was aimed to estimate the impact of health insurance status 
in adult diabetic patients on health care resource utilization and costs. Methods: 
Patients were identified in the Medical Expenditure Panel for the 2011 cycle and 
were included if they had a diabetes diagnosis and were 18 or older. Insurance 
status was defined as private, public or uninsured. results: Of the 2,180 patients, 
9% were uninsured, 31% had public health insurance and 60% had private health 
insurance. Uninsured patients were younger, more likely to be a racial minority, in 
the lower income or poor categories, with lower education compared to those with 
private insurance. After age adjustment, they were significantly less likely to be on 
Thiazolidinedione (2.03%, 11.4% and 11.17%) or anti-diabetic combination (5.2%, 
14.6% and 17.3%), for uninsured, public and private, respectively. Average health 
care resource utilization was lowest among patients without health insurances 
compared to private and public, office visits (4.9, 11.1 and 9.5), outpatient facility 
visits (0.4, 0.9 and 1) and hospital discharge (0.1, 0.3 and 0.2 ). Uninsured patients had 
lower average health care expenditures, ($4,319.5, $10,558.4, $10,377.6), emergency 
room expenditures ($110.4, $253 and $282.9) and office visits expenditures ($832.4, 
$2202.5 and $2414.6), for uninsured, public and private, respectively. conclusIons: 
It is important to assess whether lower resource utilization for uninsured patients 
impacts their current health status and is associated with long term worse out-
comes and increased health care.
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consumPTion (Dacon) for glP-1 recePTor agonisT injecTaBles from 
claims DaTa
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objectIves: This US study aimed to determine average daily dosing of liraglutide 
from a national payer perspective. Methods: This study utilized 211,184 liraglu-
tide pharmacy claims from the national Truven MarketScan® Database (10/1/2011-
9/30/2012). Patients had type 2 diabetes (DM) diagnoses x 2, no type 1 or gestational 
DM, and were ≥ 18 years old (N= 56,971). Liraglutide is typically dosed in 1.2 and 
1.8 mg/day injections. DACON was based on total daily quantity prescribed (ml 
x 6 mg/ml ÷ days’ supply). A number of claim quantities and days’ supply values 
ranged from negative/zero to very high and implausible values, which translated 
and 0.008 (D1) and 0.003, 0.013, 0.026 and 0.052 (S1) for baseline event rates of 1, 5, 10 
and 20 per year respectively. conclusIons: Nonlinear models of NSHE disutility 
typically show greater benefit per NSHE avoided in subjects with a lower frequency 
of events. As hypoglycaemia frequency increases the marginal utility gain per NSHE 
avoided decreases. Nonlinear equations provide a more plausible estimate of the 
health benefit associated with the avoidance of NSHE.
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valiDaTing The ukPDs 82 risk equaTions To conTemPorary ouTcomes 
sTuDies in TyPe 2 DiaBeTes
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objectIves: The IMS CORE Diabetes Model (CDM) is a widely published and previ-
ously validated decision support tool. The model uses the UKPDS 68 risk equations 
(REs) to predict cardiovascular events and recent studies have demonstrated the 
model’s validity to predict event rates consistent with those reported in contem-
porary T2DM outcomes studies. The CDM has been updated to include the new 
UKPDS 82 REs; consequently the objective of this study was to compare the event 
rate predictions from the UKPDS 82 and 68 REs within the CDM. Methods: A total 
of 86 validation simulations were performed to data from ACCORD, ADVANCE, VADT 
and UKPDS. Simulation cohorts mirroring baseline characteristics of each of the 
trials were generated and intensive and conventional treatment arms modeled for 
the relevant study specific follow-up. Predicted versus observed cardiovascular and 
microvascular complications and all-cause mortality (ACM) were assessed using the 
coefficient of determination (R2) goodness of fit measure. results: Across all vali-
dation studies the CDM simulations produced an R2 statistic of 0.909 using UKPDS 68 
and 0.762 using UKPDS 82. R2 statistic for MI, stroke, CHF, CV death, and ACM were 
0.773, 0.853, 0.499, 0.659 and 0.966 for the UKPDS 68 REs and 0.742, 0.848, 0.852, 0.672 
and 0.88 for the UKPDS 82 REs. Validating against 20-year outcomes data (UKPDS) 
resulted in R2 of 0.992 and 0.993 for UKPDS 68 and 82 respectively. conclusIons: 
The CDM model has been extensively validated using the UKPDS 68 risk equations 
and shown to have good predictive validity. Initial validation using the UKPDS 82 
equations show an improved fit to the UKPDS data, but less accurate external vali-
dation to recent outcomes study trials data. This may be due to necessary assump-
tions applied regarding modifiable risk factor trajectories or the functional form of 
the new equations. Further research is required to assess the robustness of these 
new equations.
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aBsoluTe anD incremenTal cosT effecTiveness resulTs in TyPe 2 
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objectIves: In cost effectiveness (CE) modeling previous studies have dem-
onstrated incorporating parameter sampling is crucial to capture the effects of 
nonlinearity in base case simulation predictions of costs and quality adjusted life 
expectancy (QALE); however, run time requirements (RTR) to reach stabilized predic-
tions may be increased. The objective of this study was to assess the RTR for analy-
ses with parameter sampling necessary to reach predefined end point stabilization 
criteria. Methods: The IMS CORE Diabetes Model was initiated using the following 
type 2 diabetes profile: 55 years of age, duration of diabetes of 5 years and baseline 
HbA1c of 7.49%. Treatment A versus B was assumed to have a 0.5% lower HbA1c 
and incremental treatment cost of $1,500 (USD) with parameter sampling using 
standard errors of 1% of mean. The model was run with 10,000 patients over 10,000 
replications. RTR was assessed in terms of replications required to reach stabiliza-
tion of absolute and incremental costs and QALEs. Stabilization was defined as point 
estimates remaining within the interval of expected value (EV) +/- tolerance (%); 
tolerance was explored in a range of 0.1% to 5% surrounding EV. results: For total 
costs and QALE the RTR required to reach stabilization was 17 and 44 replications 
respectively for a tolerance of 0.5% and 425 (costs) and 3,459 (QALE) for a tolerance 
of 0.1%. The RTR for stabilized incremental results were considerably greater: 6,886 
and 9,605 replications for costs and QALE respectively at 0.5% tolerance and 9,600 
(costs) and 10,000 (QALE) for a tolerance of 0.1%. conclusIons: Demonstrating 
the stability of simulation output is crucial to ensuring the interpretation of CE 
output is robust. The additional simulation runtime required to achieve stabilized 
incremental results should be factored into simulation study plans and convergence 
of output should be reported routinely.
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cosT-uTiliTy analyses in DiaBeTes: a sysTemaTic review anD 
PoTenTial gains from using economic eviDence
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objectIves: Diabetes-related cost-effectiveness analyses (CEA) have become more 
common, though little is known about the actual use of cost-saving services in 
real-world settings. This study systematically reviewed cost-effectiveness analyses 
of diabetes interventions, identified cost-saving diabetes services, and estimated 
potential gains from increasing use of cost-saving diabetes interventions in the 
United States. Methods: We conducted a systematic review of cost-utility analyses 
(CUAs) related to diabetes published through 2012, using the Tufts Medical Center 
CEA Registry. We also examined factors independently associated with favorable 
ratios. We used the 2008-2012 Humedica electronic medical record data to estimate 
the potential cost savings and health benefits gained by switching patients to cost-
saving diabetes interventions identified in our review. results: We identified 196 
diabetes CUAs. Most examined pharmaceuticals (55%) and focused on treatment 
rather than prevention (70%). Most used a health care payer perspective (71%) and 
were industry-sponsored (52%). Of 497 published cost-utility ratios, 82% examined 
